Horse Bleeding or EIPH (termed exercise induced-pulmonary-haemorrhage) occures during strenuous exercise is common in racehorses. However,blood (haemorrhage) appears at the nostrils (referred to as ‘epistaxis’) in only a small percentage of cases. InVictoria, the prevalence of horses bleeding for the first-time as defined as the appearance of blood at both nostrils after exercise is approximately 1.5 per 1000 starters (or 0.15%). This is comparable to that reported in Japan, Britain and South Africa, and less than that reported in Singapore, Hong Kong and the USA. Although blood appearing at the nostrils is relatively uncommon, data from large surveys performed in a number of areas around the world indicate that some degree of EIPH may occur in up to 75% of runners. Blood may be present in the trachea alone and therefore may only be evident on endoscopic examination after exercise. As it may take some time for the normal clearance mechanism of the respiratory tract to move blood into the trachea from the lungs, endoscopy may not reveal haemorrhage unless it is performed 60 minutes or more after exercise. In some cases, EIPH is not evident on endoscopy and laboratory analysis of a bronchoalveolar lavage sample (BAL or ‘lung wash’) is necessary to demonstrate its occurrence.
Why do horses bleed from their lungs?
Read complete article
Does EIPH affect performance?
Horses that bleed from the nose and ‘pull up’ in a race clearly have a reduction in performance. Indeed, most horses with blood at both nostrils finish worse than mid-field, and about half of these horses finish last. The effect of EIPH on performance is probably related to the volume of haemorrhage. A small amount of pulmonary haemorrhage may or may not significantly reduce performance, but a larger amount of bleeding can. The effects of bleeding are likely to be progressive and lung damage cumulative, ultimately leading to significant decreases in performance. This is likely because blood in the lung causes pulmonary inflammation (for at least three weeks following each episode), red cells are cleared slowly, and repeated bouts of exercise may result in repeated episodes of EIPH. Therefore, EIPH is a serious condition in racehorses and prevention or reduction of its incidence is an important issue.
How many horses die as a result of bleeding?
The answer is very few. A review of causes of death in horses at several centres in Australia and the USA reveals that less than 2% of deaths are due to severe EIPH (‘bleeding’), a small percentage are due to cardiovascular disease, whereas the majority of fatalities are as a result of serious musculoskeletal (mainly leg) injury. Between mid 1999-2005, 6 horses collapsed and died during racing in Singapore for reasons other than musculoskeletal injury. Of these, necropsy examination confirmed 3 horses to have died due to severe EIPH (i.e. 3 cases in over 30,000 runners during this period), one due to heart failure, one due to rupture of a major internal vessel, and in one case, the causes could not be determined. Furthermore, we can consider that of the 218 bleeders reported after racing during this same period, only 3 died. Horses that suffer a severe or fatal bleed during exercise typically weaken and stumble before they ‘pull up’ or collapse usually allowing time for the jockey to jump off in many cases. Serious injuries to riders are more likely to be associated with catastrophic musculoskeletal injuries and other accidents when a horse falls or veers suddenly and unexpectedly.
Rules regarding “bleeders” vary worldwide
from no or limited action to banning horses from racing after the second episode. Although individuals may differ slightly in their opinions, overall, the parties concerned (trainers, owners, jockeys, vets and stewards) seem generally satisfied with the current rules. The pre-race administration of frusemide (‘lasix’) is permitted in some states in the USA but not elsewhere. Although trainers may want frusemide permitted, there are important reasons why it is not. In the United Kingdom, there are no specific rules relating to horses exhibiting blood at the nostrils after exercise. From a regulatory perspective, each occurrence is dealt with on a case by case basis. In many jurisdictions the problem tends to be self regulating, with many trainers voluntarily retiring most horses that repeatedly bleed. However, this does not obviate the need for regulation. The Rules of Racing in Australia are designed to significantly protect the health and welfare of both horses and jockeys. In California, the administration of frusemide (‘lasix’ is permitted for horses on the ‘bleeder list’ (a list of horses reported to have blood at the nostrils or in the trachea on enodscopic examination after racing or training). If the horse is observed by officials to have bled from one or both nostrils after exercise or post-race, the following restrictions from racing 180 days; 4th episode-banned from competition for life. In South Africa the rule stipulates: 1st episode-banned from racing for 3 months; 2nd episode-banned from racing for 6 months; 3rd episode banned for life. Under the Rules of the Malayan Racing Association (which includes Singapore), a horse declared a ‘bleeder’ must not be cantered or galloped on the main training tracks for 2 months, or start in any race for 3 months, and only then after completing a 1000m trials gallop with bleeding. If the horse then races 3 times without bleeding it will revert to non-bleeder status. If the horse does bleed again before achieving this, it must not be cantered or galloped on the main training tracks for 2 months or start in a race for 6 months, and only then after completing a 1000m trial gallop without bleeding. Again, if the horse then races 3 times without bleeding it will revert to non-bleeder status. The horse is permanently banned if it suffers a 3rd bleeding attack without having reverted to non-bleeder status. The regulations for bleeders are stricter in Australia, New Zealand and Hong Kong. In Australia and NZ, horses reported by officials to have blood in both nostrils (unless in the opinion of the Stewards such bleeding was caused by external trauma) may not be exercised on any racecourse for 2 months or start in any race for 3 months, and only then after a satisfactory gallop of at least 1,000m in the presence of a Steward. If the horse bleeds on a second occasion, it is banned for life.
In Hong Kong, a bleeder is defined as a horse with pulmonary haemorrhage evident at one or both nostrils and the rule states: 1st episode-banned from the training track for 2 months and from racing for 3 months and only after passing a barrier trial; 2nd episode-banned for life.
Can bleeding be prevented or managed?
Because haemorrhage into the lung can create severe and continuing pathological reactions, it is well worth while investigating possible predisposing causes of the EIPH in any individual horse and, to implement strategies to reduce the occurrence and severity of this condition where possible. There are currently no methods and treatments which directly prevent the occurrence of EIPH, however, certain treatments and management strategies can assist in reducing the severity of haemorrhage and therefore reduce the ongoing repetitive lung damage. Any underlying inflammatory airway disease (IAD) should be diagnosed in the first instance, treated and managed appropriately thereafter. This usually requires collection of a ‘lung wash’ (BAL), which is probably best performed several weeks after the bleeding episode. Ideally, treatment includes management of the damage already present in the lung by providing the lungs with sufficient time to clear blood and to heal. A minimum time of 1 month is likely to be needed to recover from a single acute episode of EIPH. A longer period is required in many cases where chronic lesions are present. Despite months of rest and treatment, some horses do continue to bleed when faster exercise resumes. These horses should be and usually are retired. Management of horses with EIPH is aimed at reducing bleeding. Frusemide (‘Lasix’) used before strenuous exercise may decrease the severity of EIPH, but it does not prevent it from occurring. When given 90min to 4 hr before exercise, this diuretic drug produces a decrease in pressures within the blood vessels in the lung. Because of its diuretic effect, horses treated with this drug lose significant amounts of water, weigh less and may race faster. For this reason, together with the unwanted effects on detection of other drugs and, the fact that frusemide is not effective in preventing EIPH, most racing authorities do not allow the use of this drug prior to racing.
EIPH is best managed by
*Ensuring good stable management practices. This isessential for the maintenance of respiratory health and considerations should include the design of stables which provide good ventilation, provision of dust-free feed and bedding, feeding horses off the ground where possible and, allowing as much paddock time as possible. *Employing sound training practices which include the appropriate conditioning of horses, training with a knowledge of the factors which may increase the risk of bleeding (for example, strenuous exercise on an inclined treadmill may increase the risk for bleeding) and, training in such a way that these factors impact less on ‘at risk’ horses where identified. • Diagnosing small airway disease where it exists as a predisposing cause
(BAL is often required to do this) and treating this condition appropriately. Depending on the circumstances and diagnosis in each case, therapy with appropriate corticosteroids and/or bronchodilators amongst other things may be prescribed by the veterinarian to treat the underlying condition. • Diagnosing and treating any conditions causing upper respiratory tract obstruction (such as dorsal displacement of the soft palate). • Ideally, resting horses for an appropriate period of time following an episode of EIPH to provide the opportunity for blood to clear and the lungs to heal. This article was prepared by Dr Cate Steel, BVSc FACVSc.
100% NATURAL SAFE – EFFECTIVE – NO SIDE EFFECTS
FOR ORAL VETERINARY USE ONLY
STOP20 is a carefully developed product designed to reduce the incidence and severity of Exercise Induced Pulmonary Hemorrhage (EIPH), commonly known as BLEEDING, in performance horses.
STOP20 is recommended for all high performance horses (race horses, trotters, pacers, polo ponies, show jumpers, rodeo performing cattle horses, etc.) that exhibit performance deficit associated with EIPH.
IT HELPS YOUR HORSE:
” Strengthen and protect the capillary blood vessels within his lungs.
” Reestablish appetite and levels of feed intake.
” Improve the coat condition.
” Increase weight gain and alertness.
” Enhance his performance after completing the administration of the product for 20 days.
Directions: Shake bottle vigorously 10 times before drawing 10ml dose (every time you use it). Give your horse STOP 20 on an empty stomach or as far from its meals as possible. First 20 days: 10ml oral of STOP 20 twice a day during the first 10 days and then 10ml once a day during the following 10 days. Avoid great efforts for the first 10 days of supplementation; do not gallop or breeze for the first 10 days. Only very light training (walking and/or jogging) can be practiced during the first 10 days. Normal training can be resumed during the second 10 days of supplementation. Your horse is ready to race at any moment after day 20. We strongly recommend administering the dose under the tongue to allow for maximum absorption. Keep this product away from sources of energy, heat and light Do not mix different products in the same syringe
**THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FDA; THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR PREVENT ANY DISEASE. IT IS RECOMMENDED THAT YOU SEEK THE ADVISE OF A QUALIFIED VETERINARIAN FOR A PROPER AND PROFESSIONAL DIAGNOSIS.